Zeria Pharmaceutical Third Quarter 2025 Earnings: EPS: JP¥49.12 (vs JP¥68.67 in 3Q 2024)

Zeria Pharmaceutical (TSE:4559) Third Quarter 2025 Results

Key Financial Results

• Revenue: JP¥22.4b (up 5.2% from 3Q 2024).
• Net income: JP¥2.17b (down 28% from 3Q 2024).
• Profit margin: 9.7% (down from 14% in 3Q 2024). The decrease in margin was driven by higher expenses.
• EPS: JP¥49.12 (down from JP¥68.67 in 3Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zeria Pharmaceutical Earnings Insights

Looking ahead, revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are down 4.4% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Zeria Pharmaceutical's balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.